Endothelial progenitor cells and angiogenesis join the PPARty

Circulation Research

Volumn 103, Issue 1, 2008, Pages 7-9

  Biscetti, Federico ^a   Pola, Roberto ^a,b,c  

^a CATHOLIC UNIVERSITY   (Italy)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

Angiogenesis; Endothelial progenitor cells; PPARs; Prostacyclin

Indexed keywords

ARACHIDONIC ACID; CYCLOOXYGENASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTACYCLIN; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ILOPROST; INDOMETACIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS1 PROTEIN, HUMAN; SMALL INTERFERING RNA; THIAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; VASODILATOR AGENT;

ANGIOGENESIS; BIOLOGICAL ACTIVITY; BIOSYNTHESIS; CELL ACTIVITY; CELL DIFFERENTIATION; CELL PROLIFERATION; EDITORIAL; ENDOTHELIUM CELL; HUMAN; METABOLISM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL; ADULT; CELL CULTURE; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MALE; MIDDLE AGED; MONONUCLEAR CELL; NOTE; PHYSIOLOGY; REGENERATION;

ADULT; CELL PROLIFERATION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; ENDOTHELIAL CELLS; ENZYME ACTIVATION; EPOPROSTENOL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; ILOPROST; INDOMETHACIN; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; PPAR DELTA; REGENERATION; RNA, SMALL INTERFERING; STEM CELLS; THIAZOLES; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

EID: 48049123497     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.180224     Document Type: Editorial

References (36)

1. Kota BP, Huang THW, Roufgalis BD. An overview on biological mechanisms of PPARs. Pharm Res. 2005;51:85-94.
2. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark E, Chambon P, Evans RM. The nuclear receptor superfamily: the second decade. Cell. 1995;83:835-839.
3. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell. 1995;83:841-850.
4. Issemann I, Prince RA, Tugwood JD, Green S. The peroxisome proliferator-activated receptor: retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol. 1993;11:37-47.
5. Willson T, Brown P, Sternbach D, Henke B. The PPARs: From orphan receptors to drug discovery. J Med Chem. 2000;43:527-550.
6. Chawla A, Repa J, Evans R, Mangelsdorf D. Nuclear receptors and lipid physiology: Opening the X-files. Science. 2001;294:1866-1870.
7. Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2002:22:717-726.
8. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, Curtiss LK. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science. 2003;302:453-457.
9. Lefebvre AM, Peinado-Onsurbe J, Leitersdorf I, Briggs MR, Paterniti JR, Fruchart JC, Fievet C, Auwerx J, Staels B. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol. 1997:17:1756-1764.
10. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998:98:2088-2093.
11. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin. 2002;18:269-276.
12. Devroey D, Velkeniers B, Duquet W, Betz W. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'. Int J Cardiol. 2005; 101:231-235.
13. Jones AB. Peroxisome proliferator-activated receptor (PPAR) modulators: diabetes and beyond. Med Res Rev. 2001;21:540-552.
14. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661-1669.
15. Takano H, Hasegawa H, Zou Y, Komuro I. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases. Curr Pharm Des. 2004;10:2779-2786.
16. Dumasia R, Eagle KA, Kline-Rogers E, May N, Cho L, Mukherjee D. Role of PPARgamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:377-386.
17. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell. 1992;68:879-887.
18. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A. 1994:91:7355-7359.
19. Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest. 2006;116:590-597.
20. Arehart E, Stitham J, Asselbergs FW, Douville K, MacKenzie T, Fetalvero KM, Gleim S, Kasza Z, Rao Y, Martel L, Segel S, Robb J, Kaplan A, Simons M, Powell RJ, Moore JH, Rimm EB, Martin KA, Hwa J. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res. 2008;102:986-993.
21. Dusting GJ, Vane JR. Some cardiovascular properties of prostacyclin (PGI2) which are not shared by PGE2. Circ Res. 1980;46(6 Pt 2): 1183-187.
22. FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation. 1983; 67:1174-1177.
23. Fitzpatrick TM, Alter I, Corey EJ, Ramwell PW, Rose JC, Kot PA. Cardiovascular responses to PGI2 (prostacyclin) in the dog. Circ Res. 1978:42:192-194.
24. Nakagawa O, Tanaka I, Usui T, Harada M, Sasaki Y, Itoh H, Yoshimasa T, Namba T, Narumiya S, Nakao K. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation. 1994:90:1643-1647.
25. Moncada S, Higgs EA, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet. 1977;1:18-20.
26. Namba T, Oida H, Sugimoto Y, Kakizuka A, Negishi M, Ichikawa A, Narumiya S. cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. J Biol Chem. 1994:269:9986-9992.
27. Barger PM. Has angiogenesis been invited to the PPARty? J Mol Cell Cardiol. 2002;34:713-716.
28. Pola R, Gaetani E, Flex A, Aprahamian TR, Bosch-Marce M, Losordo DW, Smith RC, Pola P. Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator- activated receptors. J Mol Cell Cardiol. 2004;36:363-370.
29. Biscetti F, Gaetani E, Flex A, Aprahamian T, Hopkins T, Straface G, Pecorini G, Stigliano E, Smith RC, Angelini F, Castellot JJ Jr, Pola R. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes. 2008;57:1394-1404.
30. Biscetti F, Gaetani E, Flex A, Straface G, Pecorini G, Angelini F, Stigliano E, Aprahamian T, Smith RC, Castellot JJ, Pola R. Peroxisome Proliferator-Activated Receptor-alpha is crucial for iloprost-induced in vivo angiogenesis and VEGF upregulation. J Vasc Res. In press.
31. He T, Lu T, d'Uscio LV, Lam C-F, Lee H-C, Katusic ZS. Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells. Circ Res. 2008;103:80-88.
32. Wang CH, Ciliberti N, Li SH, Szmitko PE, Weisel RD, Fedak PW, Al-Omran M, Cherng WJ, Li RK, Stanford WL, Verma S. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation. 2004;109: 1392-1400.
33. Pistrosch F, Herbrig K, Oelschlaegel U, Richter S, Passauer J, Fischer S, Gross P. PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis. 2005; 183: 163-167.
34. Gensch C, Clever YP, Werner C, Hanhoun M, Bohm M, Laufs U. The PPAR-gamma agonist pioglitazone increases neoangiogenesis and prevents apoptosis of endothelial progenitor cells. Atherosclerosis. 2007; 192:67-74.
35. Werner C, Kamani CH, Gensch C, Bohm M, Laufs U. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. Diabetes. 2007;56: 2609-2615.
36. Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD, Bishop-Bailey D. Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol. 2007;27:63-69.